Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes

Epilepsia Open. 2023 Jun;8(2):645-650. doi: 10.1002/epi4.12697. Epub 2023 Feb 9.


Variants of SEMA6B have been identified in an increasing number of patients, often presenting with progressive myoclonus epilepsy (PME), and to lesser extent developmental encephalopathy, with or without epilepsy. The exon 17 is mainly involved, with truncating mutations causing the production of aberrant proteins with toxic gain of function. Herein, we describe three adjunctive patients carrying de novo truncating SEMA6B variants in this exon (c.1976delC and c.2086C > T novel; c.1978delC previously reported). These subjects presented with PME preceded by developmental delay, motor and cognitive impairment, worsening myoclonus, and epilepsy with polymorphic features, including focal to bilateral seizures in two, and non-convulsive status epilepticus in one. The evidence of developmental delay in these cases suggests their inclusion in the "PME plus developmental delay" nosological group. This work further expands our knowledge of SEMA6B variants causing PMEs. However, the data to date available confirms that phenotypic features do not correlate with the type or location of variants, aspects that need to be further clarified by future studies.

Keywords: SEMA6B gene mutations; cortical myoclonus; developmental and epileptic encephalopathies; progressive myoclonus epilepsy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epilepsy*
  • Humans
  • Mutation / genetics
  • Myoclonic Epilepsies, Progressive* / genetics
  • Myoclonus*
  • Phenotype
  • Semaphorins* / genetics


  • SEMA6B protein, human
  • Semaphorins